カテゴリ： Allied Market Research, 世界, 医療/バイオ

加齢黄斑変性（AMD）のグローバル市場（2023-2032）：アフリベルセプト、ラニビズマブ、その他

■ 英語タイトル：Age Related Macular Degeneration (AMD) Market By Drug Type (Aflibercept, Ranibizumab, Others), By Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23SEP135）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23SEP135
■ 発行日：2023年5月
■ 調査対象地域：グローバル
■ 産業分野：生命科学
■ ページ数：251
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[加齢黄斑変性（AMD）のグローバル市場（2023-2032）：アフリベルセプト、ラニビズマブ、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

世界の加齢黄斑変性（AMD）市場は、2022年に94億ドルと評価され、2023年から2032年までの年平均成長率は5%で、2032年には154億ドルに達すると予測されています。加齢黄斑変性（AMD）は、世界中の何百万人もの人々、特に50歳以上の人々が罹患する一般的な眼疾患です。加齢黄斑変性は、網膜の中心部である黄斑が侵される進行性の疾患で、鋭い中心視力をつかさどります。加齢黄斑変性（AMD）には、主に乾性加齢黄斑変性（AMD）と湿性加齢黄斑変性（AMD）の2種類があります。乾性加齢黄斑変性（AMD）は加齢黄斑変性（AMD）の中で最も一般的なタイプで、黄斑部の光に反応する細胞が時間の経過とともに壊れて死滅し、中心視力が徐々に失われていきます。湿性加齢黄斑変性（AMD）は、一般的ではありませんが、加齢黄斑変性（AMD）のより重篤な型であり、網膜の下で異常な血管が増殖し、体液、血液、タンパク質が漏出し、黄斑部に瘢痕化と損傷を引き起こすことで発症します。
加齢黄斑変性（AMD）市場の成長を促進する主な要因は、高齢者人口の増加、効果的な治療オプションに対する需要の急増、技術の進歩です。例えば、世界保健機関（WHO）の2022年版ファクトシートによると、2030年までに世界の6人に1人が60歳以上になると予測されています。2050年には、世界の60歳以上の人口は21億人になると予測されています。80歳以上の高齢者の数は、2050年には4億2,600万人に達すると予想されています。また、加齢黄斑変性（AMD）治療薬の需要が世界的に高まっていることも、市場の成長を後押ししています。
しかし、加齢黄斑変性治療薬に関連する高コストは、今後の市場成長を阻害すると予測されています。その一方で、加齢黄斑変性（AMD）治療における研究開発活動の増加や最新の製品承認は、近い将来の市場成長に有利な機会を提供すると期待されています。

加齢黄斑変性（AMD）市場は、薬剤タイプ、疾患タイプ、流通チャネル、地域に区分されます。薬剤タイプ別では、アフリベルセプト、ラニビズマブ、その他に分類されます。疾患タイプ別では、ドライ型加齢黄斑変性（AMD）とウェット型加齢黄斑変性（AMD）に二分されます。流通チャネル別では、病院薬局、小売薬局、オンライン薬局に細分化されています。地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、欧州のその他地域）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、アジア太平洋のその他地域）、LAMEA（ブラジル、南アフリカ、サウジアラビア、LAMEAのその他地域）で分析されます。
世界の加齢黄斑変性（AMD）市場で事業を展開する主な主要企業は、Regeneron Pharmaceuticals Inc.、Novartis AG、F. Hoffmann-La Roche Ltd.、Biogen、Bayer AG、Bausch Health Companies Inc.、Coherus Biosciences Inc.、Sanofi、Apellis Pharmaceuticals、Ionis Pharmaceuticals, Inc.です。

ステークホルダーにとっての主なメリット
2022年から2032年までの加齢黄斑変性症（amd）市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、加齢黄斑変性症（amd）市場の有力な市場機会を特定します。
加齢黄斑変性（amd）市場に関する2022年から2032年までの予測、動態分析、市場機会を明らかにします。
ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
加齢黄斑変性症（amd）市場の細分化に関する詳細な分析により、市場機会を見極めます。
各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
地域別および世界の加齢黄斑変性（amd）市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

主要市場セグメント
薬剤タイプ別
アフリベルセプト
ラニビズマブ
その他

疾患タイプ別
ウェット型加齢黄斑変性（AMD）
ドライ型加齢黄斑変性（AMD）

販売チャネル別
病院薬局
小売薬局
オンライン薬局

地域別
北米
アメリカ
カナダ
メキシコ
ヨーロッパ
フランス
ドイツ
イタリア
スペイン
イギリス
その他のヨーロッパ
アジア太平洋
中国
日本
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
その他の地域

主要市場プレイヤー
○ F. Hoffmann-La Roche Ltd.
○ Coherus Biosciences Inc
○ Biogen
○ Regeneron Pharmaceuticals Inc.
○ Ionis Pharmaceuticals, Inc.
○ Novartis AG
○ Bayer AG
○ Bausch Health Companies Inc.
○ Apellis Pharmaceuticals Inc.
○ Sanofi S.A.

第1章：イントロダクション
第2章：エグゼクティブサマリー
第3章：市場概要
第4章：加齢黄斑変性（AMD）市場、薬剤タイプ別
第5章：加齢黄斑変性（AMD）市場、疾患タイプ別
第6章：加齢黄斑変性（AMD）市場、流通チャネル別
第7章：加齢黄斑変性（AMD）市場、地域別
第8章：競争状況
第9章：企業情報

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in geriatric population
3.4.1.2. Increase in incidences of age-related macular degeneration (AMD) across the globe

3.4.2. Restraints
3.4.2.1. High cost of treatment

3.4.3. Opportunities
3.4.3.1. Increase in number of pipelines drug

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Aflibercept
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Ranibizumab
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Wet Age Related Macular Degeneration (AMD)
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Dry Age Related Macular Degeneration (AMD)
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacy
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail Pharmacy
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online Pharmacy
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Disease Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Disease Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Disease Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Disease Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Disease Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. France
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Disease Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. Germany
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Disease Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. Italy
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Disease Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Spain
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Disease Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. UK
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Disease Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Disease Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Disease Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Disease Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Disease Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Disease Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Disease Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Disease Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Disease Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Disease Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Disease Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Disease Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Disease Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Disease Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Regeneron Pharmaceuticals Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Novartis AG
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. F. Hoffmann-La Roche Ltd.
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Biogen
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.4.7. Key strategic moves and developments
9.5. Bayer AG
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Coherus Biosciences Inc
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.6.7. Key strategic moves and developments
9.7. Sanofi S.A.
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Apellis Pharmaceuticals Inc.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.8.7. Key strategic moves and developments
9.9. Bausch Health Companies Inc.
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Ionis Pharmaceuticals, Inc.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 02. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR AFLIBERCEPT, BY REGION, 2022-2032 ($MILLION)
TABLE 03. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RANIBIZUMAB, BY REGION, 2022-2032 ($MILLION)
TABLE 04. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 06. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR WET AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
TABLE 07. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR DRY AGE RELATED MACULAR DEGENERATION (AMD), BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 09. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR HOSPITAL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 10. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR RETAIL PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 11. AGE RELATED MACULAR DEGENERATION (AMD) MARKET FOR ONLINE PHARMACY, BY REGION, 2022-2032 ($MILLION)
TABLE 12. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 18. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 20. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 21. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 24. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 27. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 31. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 32. FRANCE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 33. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 35. GERMANY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 37. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 38. ITALY AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 40. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 41. SPAIN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 43. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 44. UK AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 53. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 54. CHINA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 55. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 57. JAPAN AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 59. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 60. AUSTRALIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 63. INDIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 71. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 75. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DRUG TYPE, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA AGE RELATED MACULAR DEGENERATION (AMD) MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REGENERON PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 87. REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 88. REGENERON PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 89. REGENERON PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 90. NOVARTIS AG: KEY EXECUTIVES
TABLE 91. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 92. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 93. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 94. NOVARTIS AG: KEY STRATERGIES
TABLE 95. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 96. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 97. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 98. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
TABLE 99. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
TABLE 100. BIOGEN: KEY EXECUTIVES
TABLE 101. BIOGEN: COMPANY SNAPSHOT
TABLE 102. BIOGEN: PRODUCT SEGMENTS
TABLE 103. BIOGEN: PRODUCT PORTFOLIO
TABLE 104. BIOGEN: KEY STRATERGIES
TABLE 105. BAYER AG: KEY EXECUTIVES
TABLE 106. BAYER AG: COMPANY SNAPSHOT
TABLE 107. BAYER AG: PRODUCT SEGMENTS
TABLE 108. BAYER AG: PRODUCT PORTFOLIO
TABLE 109. COHERUS BIOSCIENCES INC: KEY EXECUTIVES
TABLE 110. COHERUS BIOSCIENCES INC: COMPANY SNAPSHOT
TABLE 111. COHERUS BIOSCIENCES INC: PRODUCT SEGMENTS
TABLE 112. COHERUS BIOSCIENCES INC: PRODUCT PORTFOLIO
TABLE 113. COHERUS BIOSCIENCES INC: KEY STRATERGIES
TABLE 114. SANOFI S.A.: KEY EXECUTIVES
TABLE 115. SANOFI S.A.: COMPANY SNAPSHOT
TABLE 116. SANOFI S.A.: PRODUCT SEGMENTS
TABLE 117. SANOFI S.A.: PRODUCT PORTFOLIO
TABLE 118. APELLIS PHARMACEUTICALS INC.: KEY EXECUTIVES
TABLE 119. APELLIS PHARMACEUTICALS INC.: COMPANY SNAPSHOT
TABLE 120. APELLIS PHARMACEUTICALS INC.: PRODUCT SEGMENTS
TABLE 121. APELLIS PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
TABLE 122. APELLIS PHARMACEUTICALS INC.: KEY STRATERGIES
TABLE 123. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 124. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 125. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 126. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 127. IONIS PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 128. IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 129. IONIS PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 130. IONIS PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • セルカウント（細胞計数）のグローバル市場（2023-2032）：装置、付属品、消耗品
  • 迷走神経刺激療法（VNS）のグローバル市場（2023-2032）：植込み型VNSデバイス、体外用VNSデバイス
  • 試験・検査・認証（TIC）のグローバル市場（2023-2032）：試験・検査・認証（TIC）
  • 天然繊維複合材料（NFC）のグローバル市場（2023-2032）：木材、綿、亜麻、ケナフ、麻、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23SEP135 )"加齢黄斑変性（AMD）のグローバル市場（2023-2032）：アフリベルセプト、ラニビズマブ、その他" (英文：Age Related Macular Degeneration (AMD) Market By Drug Type (Aflibercept, Ranibizumab, Others), By Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2023-2032)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。